The development process of new
pharma solutions by ViroPharma is being accelerated thanks to its use of parallel chromatography.
Using the parallel chromatography procedure, the
pharma firm explains that it is able to double the capacity of its manufacturing line by running across multiple shifts.
On May 26th, ViroPharma disclosed that it had supplied Cinryze manufactured through the parallel chromatography process for use in patients with hereditary angioedema.
Now it has filed a Prior Approval Supplement with the US
Food and Drug Administration to allow it to commercialise the drug manufactured through the industrial scale process.
The request hinges on industrial-scale production of the drug matching the quality of the previous scale in use.
ViroPharma says that it has the data to demonstrate this being the case and expects to see approval granted by the end of the year.
Cinryze is an injectible medicine which tackles hereditary angioedema by preventing painful attacks and helping to reduce the risk of swelling.
Product directory
